Company news

Qyuns Therapeutics Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Voluntary announcement exclusive license agreement with caldera therapeutics for a preclinical bispecific antibody program targeting TL1A and IL-17

November 5, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 5, 2026

Documents on Display

October 27, 2026

Form of proxy for the extraordinary general meeting to be held on Friday, November 13, 2026

October 27, 2026

Notice of the 2026 first extraordinary general meeting

October 27, 2026

(1) Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; (2) proposed appointment of director and determination of the director's remuneration; and (3) notice of the 2026 first extraordinary general meeting

October 27, 2026

Announcement book closure period for extraordinary general meeting

October 26, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

Voluntary announcement phase III clinical study results of Oturkibart (QX005N) for treatment of prurigo nodularis presented as a late-breaking oral presentation at EADV 2026

October 1, 2026

List of directors and their roles and functions

September 22, 2026

Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; and resignation and proposed appointment of non-executive director

September 22, 2026

2026 Interim report

September 21, 2026

A Decade of Persistent Steps, Aspiring for a Thousand Miles: Qyuns' Grand 10th Anniversary Celebration Held Successfully

June 16, 2025

Decks